A Number Of Frightening Black Swans Will Surface In 2014

kingworldnews.com / February 24, 2014
With gold and silver surging, oil remaining over $100, and the US Dollar Index desperately trying to cling to the 80 level, today a man who has been involved in the financial markets for 50 years, and whose business partner is billionaire Eric Sprott, warned King World News that a number of black swans are going to surface in 2014.  John Embry also discussed the implications of the coming chaos for investors around the world.
Embry:  “I’m offended by some of the propaganda coming out of the mainstream media.  The World Gold Council came out with some figures for Chinese demand that dramatically understated the truth, and essentially falsified the demand for gold from China….
READ MORE

Please share this article

Monster Beverage (NASDAQ: MNST) 1,000% Gainer Set to Return Additional Double-Digit Profits

When a stock is up more than 30% in just the past three months, you can say it has "the juice." In the case of Southern California-based Monster Beverage (NASDAQ: MNST) "the juice" is generated by its uber-cool energy drinks.
The company's namesake beverage, Monster Energy Drink, is what propelled it into national and global prominence. But like any good beverage company, Monster offers all sorts of brands for all sorts of tastes, including Java Monster, Worx Energy, Peace Tea, Hansen's, Blue Sky and a host of others.
The success of Monster's existing brands has made it one of the biggest beverage industry success stories of the past decade, and that success has translated into huge success on Wall Street. MNST stock is up 1,000% in the past 10 years, easily vaulting the shares to rock star status among investors.  (more)

Please share this article

American Eagle Outfitters (NYSE: AEO)

American Eagle Outfitters, Inc., together with its subsidiaries, operates as an apparel and accessories retailer in the United States and Canada. The company’s retail stores offer denims, sweaters, fleece, outerwear, graphic T-shirts, footwear, and accessories for 15 to 25-year old men and women under the American Eagle Outfitters brand name; and intimates and personal care products for girls under the aerie brand name. As of February 2, 2013, it operated 893 American Eagle Outfitters stores and 151 aerie stand-alone stores, as well as 49 franchised stores in 13 countries. The company also sells and ships merchandise through its e-commerce Websites, including ae.com and aerie.com to 81 countries worldwide.
To review American’s stock, please take a look at the 1-year chart of AEO (American Eagle Outfitters, Inc.) below with my added notations:

Over the last (6) months AEO has traded mostly sideways, but over the most recent month the stock has formed a nice trend line of support (red). Always remember that any (2) points can start a trend line, but it’s the 3rd test and beyond that confirm its importance. So, AEO’s trend line is important to the stock since it has been tested on three different occasions. In addition, the stock has a key level at $14 (blue) that is currently acting as resistance.

The Tale of the Tape: AEO has a trend line support and a $14 resistance. A long position could be entered on a break above $14, with a stop placed below that level. A short position could be entered if AEO were to break below $13.50, which would be a break of the trend line support.
Please share this article

Acorda Therapeutics Inc (NASDAQ: ACOR)

Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally.
To review Acorda’s stock, please take a look at the 1-year chart of ACOR (Acorda Therapeutics, Inc.) below with my added notations:

Over the last year ACOR has consistently moved lower. During that time the stock had also formed a nice trend line of resistance (blue). Always remember that any (2) points can start a trend line, but it’s the 3rd test and beyond that confirm its importance. As you can see, ACOR’s trend line had been tested multiple times. On Monday the stock finally broke through that trend line.

The Tale of the Tape: ACOR has broken above its trend line resistance. A long position could be entered on a pullback to the trend line, with a stop placed below that level. A short position could be entered if ACOR were to break back below the trendline.
Please share this article

Michael Kors (NYSE: KORS) The Only Luxury Retailer Worth Buying Now Could Soar 33%

When a company markedly outperforms its peer group, it always captures my attention. Why, I wonder, has it done so much better than its direct competitors?
In a little over two years, Michael Kors (NYSE: KORS) shares have surged almost 300%. KORS opened at $25 on the day of its December 2011 IPO and now trades near its all-time high just under $100. In contrast, Coach (NYSE: COH) has tumbled 20% during that time frame, while Ralph Lauren (NYSE: RL) is only up about 13%.
Michael Kors' expensive handbags and watches, among its other luxury goods, are coveted. To satisfy strong customer demand, the company is working to open new stores around the world. In the past three quarters, it added 133 new outlets, 91 of which are company-owned and 42 are licensed. Michael Kors now has 533 stores worldwide. (more)

Please share this article

The One Thing You Must Know to Hit It Big with a Biotech Stock

When you're evaluating a biotech, or even a full-fledged pharmaceutical company, you'll want to look at its product pipeline, upcoming catalysts, and financial indicators.
But the most important asset it possesses, the heartbeat that drives everything else, is its intellectual property (patent) portfolio...
That's what will make it attractive for acquisition, merger, or licensing deals.
And it's what protects its products from marauding generic drug manufacturers, who will produce copycat therapies and sell them at cutthroat prices.
For a drug development company, that spells disaster.
When a drug goes generic, it's not unusual for the original brand manufacturer's market share to drop more than 40%...(more)

Please share this article

Top Three Closed-End Funds With Yields Over… 8%

Open Your Eyes to Closed-End Funds
Closed-end funds (CEFs) are different from open-end funds (commonly known as mutual funds) in some significant ways.
For example, CEFs trade on an exchange intraday, just like exchange-traded funds (ETFs).
However, mutual funds and ETFs issue and redeem shares at their net asset value (NAV), so the number of shares fluctuates due to demand.
Conversely, CEFs have a fixed number of shares. The price of a CEF is determined by supply and demand in the secondary market, so the shares can trade at a persistent premium or discount to the underlying NAV.  (more)

Please share this article